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Letters to the Editor
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Fig. 1. No evidence for Trim24 isoforms. (A) UCSC screen shot of ChIP-seq data
for Pol II, H3K4me3 and for the general transcription factors TBP, TFIIE, TFIIB, and
TAF3 as well as HNF4A at the Trim24 locus. (B) Read coverage and splice junctions
at the Trim24 locus are depicted in red for wild-type sample and in blue for
Trim24ex4/ sample. Ensembl release 76 annotations are represented. RNA-seq
reads were aligned on mm10 using Tophat2 [7]. (C) Most reliable ORF prediction
on Trim24-002 without exon 4 performed using ATGpr (Salamov et al., 1998).To the Editor:
The Losson and Davidson laboratories have investigated the role
of the Trim24 gene in mouse physiology. Germ line knockout of
the Trim24 gene involved targeted deletion of exon 4 [1].
Trim24ex4/ mice were viable and fertile, but developed hepato-
cellular carcinoma with 100% penetrance after 18 months of age.
Hepatocarcinogenesis involved a progressive multi-step process;
with altered cell cycle, clear-cell foci of altered hepatocytes,
hepatoadenoma and ﬁnally hepatocarcinoma [1]. A very similar
series of events was seen when Trim24 was selectively inacti-
vated in hepatocytes [2]. Gene expression studies showed that
the antiviral interferon response is the main pathway altered at
an early age [3,4].
The Barton laboratory [5] recently analyzed a Trim24 knockout
mouse generated by deleting Trim24 exon 1. Trim24ex1/ mice
also spontaneously develop hepatocarcinoma with a time-course
resembling that originally described. Attention is drawn to several
differenceswith the Trim24ex4/model that Jiang et al. arguemay
be due to the persistence of alternatively spliced isoforms
generated from our Trim24ex4/ allele. Many potential Trim24
isoforms are reported in public databases (Fig. 1A) corresponding
to alternative splicing events or use of intragenic promoters.
A spliced Trim24ex4/ transcript initiates from the most
upstream transcription start site (TSS) as attested by the presence
of trimethylated histone H3 lysine 4 (H3K4me3) and paused RNA
polymerase II (Pol II) [4]. No other sites of H3K4me3 and Pol II
accumulation were seen within the gene body indicating no use
of alternative intragenic promoters. This is conﬁrmed in an inde-
pendent data set [6] where Pol II and the general transcription
machinery are found only at the upstream TSS (Fig. 1A). There
is therefore no evidence for use of alternative Trim24 intragenic
promoters in mouse liver.
We analysed the wild-type total RNA-seq data [4] and found
only exon-junction reads consistent with generation of the
Trim24-001 and Trim24-002 isoforms in the wild-type liver. For
Trim24ex4/, the Trim24-002 isoform is predominant, with
junction fragments between exons 3 and 5 consistent with the
absence of exon 4. In contrast, we found no exon-junction frag-
ments indicative of other exon-skipping events and generation
of other isoforms.
The only reliable ORF produced from the Trim24ex4/ allele
lacking exon 4 would initiate at the ﬁrst ATG, terminate prema-
turely at a nonsense codon following amino acid 214 and encode
a protein comprising of the RING ﬁnger, but lacking all other
known domains of the protein, coiled-coil homo/heterodimeriza-
tion domain, the HP1 and nuclear receptor interaction domains
and the chromatin binding PHD-ﬁnger-bromodomain unit. It is
not known whether such a short truncated Trim24 protein is
stable, but it is highly improbable that it could mimic any of
the normal functions of Trim24.Journal of Hepatology 2015 vol. 63 j 276–288
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We thus believe that the minor differences between the
Trim24ex4/ and Trim24ex1/ mouse models are more likely
accounted for by differences in genetic backgrounds of the mice
and the ages at which gene expression was analyzed rather than
the existence of Trim24 isoforms arising from the Trim24ex4/
allele that were overlooked in our previous studies and for which
we ﬁnd no evidence.
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Coagulation and ﬁbrosis: A potential non-negligible
target of statins in chronic hepatitis
To the Editor:
We read with interest the paper by Simon and colleagues demon-
strating a reduced rate of ﬁbrosis progression in HCV positive
patients receiving a chronic treatment with statins [1]. This
observation could be clinically relevant in a scenario where we
have not effective antiﬁbrotic drugs. It emerges alongside the
growing agreement on the safety of statins in patients with liver
disease, including cirrhosis [2]. Statins inhibit 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase and interfere with
the ‘‘mevalonate pathway’’. As a result, they exert a complex
modulation of anti-inﬂammatory and anti-proliferative proper-
ties of the endothelium. This also occurs at sinusoidal level where
endothelial cells regulate the activation of hepatic stellate cells
(HSCs) toward a myo-ﬁbroblast phenotype [3]. The clinical
results of Simon stimulated us to speculate on the mechanisms
behind the antiﬁbrotic effect of statins in chronic liver disease
along with their ability to preserve the endothelial function.
Among the pleiotropic effects of statins, their anti-inﬂamma-
tory properties have often been considered potentially useful in
chronic liver diseases [4]. However, Simon unexpectedly showed
that in his series statins reduced the rate of ﬁbrosis indepen-
dently from the reduction of the inﬂammatory activity index.
As a consequence, the authors suggested that the effect of statins
on liver histology was due to the ability of this class of drugs to
improve the endothelial function rather than to reduce
inﬂammation. In line with this hypothesis, Maieron et al. demon-
strated that liver ﬁbrosis at different stages of chronic HCV infec-
tion correlates with the plasma levels of von Willebrand factor
(vWF), a marker of endothelial dysfunction involved in hemosta-
sis [5]. Interestingly, some clinical studies observed that statins
may reduce the plasma levels of vWF (Table 1). Unfortunately,
the study by Simon et al. did not include the dosage of vWF, an
assessment that would have been useful to conﬁrm any interre-
lationships between endothelial dysfunction and ﬁbrosis pro-
gression. In our opinion, the complex interaction between
endothelium and HSCs could also be affected by the impairment
of the coagulation function in patients with liver disease as sug-
gested by different experimental observations [6]. First, thrombin
per se can activate HSCs via PAR-1 and PAR-4 (protease-activated
receptor) receptors promoting a myo-ﬁbroblast phenotype.
Second, the occurrence of micro-thrombi in small hepatic and
portal venules can lead to sinusoidal ischemic injury and hepato-
cyte apoptosis, as proposed by the ‘‘parenchymal extinction the-
ory’’. Third, antiﬁbrotic effects have been obtained by
anticoagulation in animal models and humans, with encouraging
results. Statins can interfere with several of the mentioned mech-
anisms. First, they can decrease the expression of tissue factor,
reducing thrombin formation [7]. Second, they can increase
endothelial expression of thrombomodulin that converts throm-
bin into an anticoagulant enzyme through the activation of
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